Literature DB >> 21917954

Comparative analysis of poxvirus orthologues of the vaccinia virus E3 protein: modulation of protein kinase R activity, cytokine responses, and virus pathogenicity.

Chad Myskiw1, Janilyn Arsenio, Craig Hammett, Rebekah van Bruggen, Yvon Deschambault, Nicole Beausoleil, Shawn Babiuk, Jingxin Cao.   

Abstract

Poxviruses are important human and animal pathogens that have evolved elaborate strategies for antagonizing host innate and adaptive immunity. The E3 protein of vaccinia virus, the prototypic member of the orthopoxviruses, functions as an inhibitor of innate immune signaling and is essential for vaccinia virus replication in vivo and in many human cell culture systems. However, the function of orthologues of E3 expressed by poxviruses of other genera with different host specificity remains largely unknown. In the present study, we characterized the E3 orthologues from sheeppox virus, yaba monkey tumor virus, swinepox virus, and myxoma virus for their ability to modulate protein kinase R (PKR) function, cytokine responses and virus pathogenicity. We found that the E3 orthologues of myxoma virus and swinepox virus could suppress PKR activation and interferon (IFN)-induced antiviral activities and restore the host range function of E3 in HeLa cells. In contrast, the E3 orthologues from sheeppox virus and yaba monkey tumor virus were unable to inhibit PKR activation. While the sheeppox orthologue was unable to restore the host range function of E3, the yaba monkey tumor virus orthologue partially restored E3-deficient vaccinia virus replication in HeLa cells, correlated with its ability to suppress IFN-induced antiviral activities. Moreover, poxvirus E3 orthologues show varying ability to inhibit the induction of antiviral and proinflammatory cytokines. Despite these in vitro results, none of the E3 orthologues tested was capable of restoring pathogenicity to E3-deficient vaccinia virus in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917954      PMCID: PMC3209343          DOI: 10.1128/JVI.05505-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

Review 1.  Poxviruses and immune evasion.

Authors:  Bruce T Seet; J B Johnston; Craig R Brunetti; John W Barrett; Helen Everett; Cheryl Cameron; Joanna Sypula; Steven H Nazarian; Alexandra Lucas; Grant McFadden
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis.

Authors:  S B Lee; M Esteban
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

3.  Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.

Authors:  H W Chang; B L Jacobs
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

4.  Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.

Authors:  S K Sambhi; M R Kohonen-Corish; I A Ramshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  The genomes of sheeppox and goatpox viruses.

Authors:  E R Tulman; C L Afonso; Z Lu; L Zsak; J-H Sur; N T Sandybaev; U Z Kerembekova; V L Zaitsev; G F Kutish; D L Rock
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo.

Authors:  Sangeetha Vijaysri; Latha Talasela; Andrew A Mercer; Colin J Mcinnes; Bertram L Jacobs; Jeffrey O Langland
Journal:  Virology       Date:  2003-09-15       Impact factor: 3.616

7.  The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.

Authors:  H W Chang; J C Watson; B L Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

8.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

9.  Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus.

Authors:  Craig R Brunetti; Hiroko Amano; Yoshiaki Ueda; Jing Qin; Tatsuo Miyamura; Tetsuro Suzuki; Xing Li; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene.

Authors:  E Beattie; K L Denzler; J Tartaglia; M E Perkus; E Paoletti; B L Jacobs
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

View more
  24 in total

1.  Poxviral protein E3-altered cytokine production reveals that DExD/H-box helicase 9 controls Toll-like receptor-stimulated immune responses.

Authors:  Alan Dempsey; Sinead E Keating; Michael Carty; Andrew G Bowie
Journal:  J Biol Chem       Date:  2018-08-15       Impact factor: 5.157

2.  Ectromelia virus accumulates less double-stranded RNA compared to vaccinia virus in BS-C-1 cells.

Authors:  Tiffany R Frey; Michael H Lehmann; Colton M Ryan; Marie C Pizzorno; Gerd Sutter; Adam R Hersperger
Journal:  Virology       Date:  2017-09       Impact factor: 3.616

3.  Mutational analysis of vaccinia virus E3 protein: the biological functions do not correlate with its biochemical capacity to bind double-stranded RNA.

Authors:  Kevin J Dueck; YuanShen Sandy Hu; Peter Chen; Yvon Deschambault; Jocelyn Lee; Jessie Varga; Jingxin Cao
Journal:  J Virol       Date:  2015-03-04       Impact factor: 5.103

4.  Species-specific inhibition of antiviral protein kinase R by capripoxviruses and vaccinia virus.

Authors:  Chorong Park; Chen Peng; Greg Brennan; Stefan Rothenburg
Journal:  Ann N Y Acad Sci       Date:  2019-01-15       Impact factor: 5.691

5.  Genome scale evolution of myxoma virus reveals host-pathogen adaptation and rapid geographic spread.

Authors:  Peter J Kerr; Matthew B Rogers; Adam Fitch; Jay V Depasse; Isabella M Cattadori; Alan C Twaddle; Peter J Hudson; David C Tscharke; Andrew F Read; Edward C Holmes; Elodie Ghedin
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

6.  Ectromelia virus lacking the E3L ortholog is replication-defective and nonpathogenic but does induce protective immunity in a mouse strain susceptible to lethal mousepox.

Authors:  Tiffany R Frey; Katherine S Forsyth; Maura M Sheehan; Brian C De Haven; Julia G Pevarnik; Erin S Hand; Marie C Pizzorno; Laurence C Eisenlohr; Adam R Hersperger
Journal:  Virology       Date:  2018-03-27       Impact factor: 3.616

7.  A survey of host range genes in poxvirus genomes.

Authors:  Kirsten A Bratke; Aoife McLysaght; Stefan Rothenburg
Journal:  Infect Genet Evol       Date:  2012-12-23       Impact factor: 3.342

8.  The multi-functional reovirus σ3 protein is a virulence factor that suppresses stress granule formation and is associated with myocardial injury.

Authors:  Yingying Guo; Meleana M Hinchman; Mercedes Lewandrowski; Shaun T Cross; Danica M Sutherland; Olivia L Welsh; Terence S Dermody; John S L Parker
Journal:  PLoS Pathog       Date:  2021-07-08       Impact factor: 6.823

9.  Comparative Pathogenesis, Genomics and Phylogeography of Mousepox.

Authors:  Carla Mavian; Alberto López-Bueno; Rocío Martín; Andreas Nitsche; Antonio Alcamí
Journal:  Viruses       Date:  2021-06-15       Impact factor: 5.048

10.  Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity.

Authors:  Marie-Line Goulet; David Olagnier; Zhengyun Xu; Suzanne Paz; S Mehdi Belgnaoui; Erin I Lafferty; Valérie Janelle; Meztli Arguello; Marilene Paquet; Khader Ghneim; Stephanie Richards; Andrew Smith; Peter Wilkinson; Mark Cameron; Ulrich Kalinke; Salman Qureshi; Alain Lamarre; Elias K Haddad; Rafick Pierre Sekaly; Suraj Peri; Siddharth Balachandran; Rongtuan Lin; John Hiscott
Journal:  PLoS Pathog       Date:  2013-04-25       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.